Posted on 1/7/20
GNS Healthcare Announces Strategic Investment from Merck Global Health Innovation Fund
GNS Healthcare (GNS), a leading precision medicine AI company, announced today an extension of their Series D funding round, bringing the amount raised to $28 million
Posted on 1/7/20
Curis Announces Option and License Agreement with ImmuNext
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into . . .
Posted on 1/7/20
Medicinal Genomics Partners with Analogic Solutions
Medicinal Genomics Corp. (MGC), a pioneer in genomics and blockchain technology to improve the yield, safety, and transparency of cannabis, today announced its partnership with Analogic . . .
Posted on 1/7/20
Bioasis Announces Shares for Debt Transaction
GUILFORD, Conn.--(BUSINESS WIRE)--BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the . . .
Posted on 1/7/20
Epizyme Announces Exercise of $50 Million Option with Royalty Pharma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that it exercised its option to sell $50 million of . . .
Posted on 1/6/20
Is Cigna's Stock a Buy?
Healthcare provider Cigna (NYSE:CI) was having a lackluster 2019 until the past three months; since then, its stock has been soaring more than 35%, soundly outperforming . . .
Posted on 1/6/20
Here's Why Bristol-Myers Squibb Jumped 12.7% in December
What happenedShares of Bristol-Myers Squibb (NYSE:BMY) gained nearly 13% last month, according to data from S&P Global Market Intelligence. The trek higher capped off a solid . . .
Posted on 1/6/20
Assessing Akebia Therapeutics
SummaryNephrology therapy concern Akebia Therapeutics, Inc. is down ~65% from its 2014 IPO price of $17 even with a recent rally.Two critical Phase 3 readouts are . . .
Posted on 1/6/20
Is Vertex Pharmaceuticals Stock a Buy?
Vertex Pharmaceuticals (NASDAQ:VRTX) hit paydirt when the company's first medicine to treat the underlying causes of cystic fibrosis (CF) -- a rare condition that affects several . . .
Posted on 1/6/20
Better Buy: Gilead Sciences vs. Biogen
Gilead Sciences (NASDAQ:GILD) and Biogen (NASDAQ:BIIB) are two cheap stocks for healthcare investors to consider today. Neither stock has performed particularly well over the past few . . .
Posted on 1/6/20
Here's Why Deciphera Pharmaceuticals Rose 31.6% in December
What happenedShares of Deciphera Pharmaceuticals (NASDAQ:DCPH) lept over 31% last month, according to data from S&P Global Market Intelligence. The monthly run-up topped 45% at one . . .
Posted on 1/3/20
Peak Physical Therapy & Sports Performance to Open New Clinic at the Wolves Den Sports Complex in Pembroke
Peak Physical Therapy & Sports Performance, a South Shore practice specializing in unique programs that provide comprehensive treatment in orthopedic, spine and sports medicine specialties, will . . .
Posted on 1/3/20
Charles River Laboratories Completes the Acquisition of HemaCare
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of HemaCare Corporation (OTCMKTS: HEMA) for approximately . . .
Posted on 1/3/20
Cigna: The Health Services Powerhouse (Part 2)
SummaryThe HMO industry has consolidated in recent years.Cigna has enjoyed annual revenue growth of 11% and compound annual earnings per share growth of 15% from 2009-18.Valuation . . .
Posted on 1/3/20
Intellia Therapeutics: A Look Back At 2019 And Forward To 2020
SummaryIntellia made significant advancements throughout 2019.The company's partnership with Novartis remains uncertain.2020 could see wild fluctuations in the stock price.As 2019 comes to a close, it's . . .
Posted on 1/10/20
Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has entered into a . . .
Posted on 1/2/20
Dicerna Announces Closing of Agreement With Novo Nordisk
LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the closing of the discovery and development . . .
Posted on 1/2/20
Diversified Healthcare Trust and Five Star Senior Living Complete Restructuring
NEWTON, Mass.--(BUSINESS WIRE)--Diversified Healthcare Trust (Nasdaq: DHC) and Five Star Senior Living Inc. (Nasdaq: FVE) today announced that the previously announced restructuring of their business arrangements . . .
Posted on 1/2/20
Implanet Launches A Reverse Stock Split
BORDEAUX, France & BOSTON--(BUSINESS WIRE)--IMPLANET (Paris:ALIMP) (OTCQX:IMPZY) (Euronext Growth: ALIMP, FR0010458729, eligible for PEA-PME equity savings plans) (the ‘Company’), a medical technology company specializing in vertebral . . .
Posted on 1/1/20
Hologic Completes Divestiture of Cynosure Medical Aesthetics Business
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that it has completed the previously announced divestiture of its Cynosure medical aesthetics business to an affiliate of . . .
Posted on 1/13/20
Fresenius Medical Care North America Continues to Support National Kidney Foundation with Record Fundraising
Fresenius Medical Care North America (FMCNA), the largest provider of dialysis products and services, has raised a record amount of funds to support the goals and . . .
Posted on 12/24/19
These Were the 10 Best Healthcare Stocks of 2019
Biotech, hands down, wins the race for out-performance in the healthcare sector. Delivering new, valuable medicines has proven to be a winning strategy, even if the . . .
Posted on 12/24/19
Athenex Mixed Results, Boston Scientific Approval, And Other News: The Good, Bad, And Ugly Of Biopharma
SummaryAthenex tumbled on mixed data.Boston Scientific received an approval, DARE an IND.Conformis Biosciences got an FDA warning.Looking for more stock ideas like this one? Get them . . .
Posted on 12/24/19
Karuna Therapeutics' Crash Reminds Investors How Dangerous Biotech Stocks Can Be
Investing in biotech stocks can be very risky. Positive results from a clinical trial can send a stock's valuation through the roof, while a poor result . . .
Posted on 12/24/19
Bioasis Completes Bridge Financing Transaction
GUILFORD, Conn.--(BUSINESS WIRE)--BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain . . .

